| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
64,210,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
141 |
Avg
Vol: |
1,513,129 |
| 52
Week Range: |
$0.000001 - $0.238 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
410,196 |
425,190 |
| Total Sell Value |
$0 |
$0 |
$28,714 |
$38,646 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lampert Mark N |
10% Owner |
– – • |
2018-11-14 |
4 |
B |
$1.34 |
$281,735 |
D/D |
210,250 |
5,776,813 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-11-13 |
4 |
B |
$1.35 |
$815,681 |
D/D |
604,208 |
5,683,853 |
2.45 |
- |
|
| Perkins Adelene Q |
Chief Executive Officer |
• • – |
2018-10-01 |
4 |
AS |
$2.82 |
$14,100 |
D/D |
(5,000) |
609,561 |
|
- |
|
| Kutok Jeffery |
Chief Scientific Officer |
• – – |
2018-08-16 |
4 |
AS |
$2.00 |
$12,266 |
D/D |
(6,133) |
0 |
|
- |
|
| Kutok Jeffery |
Chief Scientific Officer |
• – – |
2018-08-15 |
4 |
AS |
$2.01 |
$16,421 |
D/D |
(8,180) |
6,133 |
|
- |
|
| Kutok Jeffery |
Chief Scientific Officer |
• – – |
2018-06-22 |
4 |
AS |
$2.00 |
$28,695 |
D/D |
(14,313) |
14,313 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-06-21 |
4 |
B |
$1.65 |
$702,126 |
D/D |
425,531 |
1,167,191 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-06-19 |
4 |
B |
$1.65 |
$5,802,324 |
D/D |
3,516,560 |
1,130,366 |
2.45 |
- |
|
| Beier David W |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.75 |
$10,000 |
D/D |
5,714 |
5,714 |
|
- |
|
| Berkowitz Jeffrey |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.75 |
$40,000 |
D/D |
22,857 |
58,988 |
|
- |
|
| Evnin Anthony B |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.75 |
$19,999 |
D/D |
11,428 |
130,013 |
|
- |
|
| Smith Ian F |
Director |
– • – |
2018-06-12 |
4 |
A |
$1.75 |
$40,000 |
D/D |
22,857 |
45,845 |
|
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-04-10 |
4 |
B |
$2.00 |
$2,020,000 |
D/D |
1,010,000 |
950,473 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2018-04-09 |
4 |
B |
$1.90 |
$950,000 |
D/D |
500,000 |
853,020 |
2.45 |
- |
|
| Perkins Adelene Q |
Chief Executive Officer |
• • – |
2018-03-05 |
4 |
AS |
$2.78 |
$13,890 |
D/D |
(5,000) |
607,252 |
|
- |
|
| Perkins Adelene Q |
Chief Executive Officer |
• • – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
69,924 |
612,252 |
|
- |
|
| Tasker Seth A |
General Counsel |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
22,351 |
41,284 |
|
- |
|
| Bloch Lawrence E |
President |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
37,881 |
626,133 |
|
- |
|
| Kutok Jeffery |
Chief Scientific Officer |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
28,626 |
28,626 |
|
- |
|
| Bloch Lawrence E |
President |
• – – |
2017-12-06 |
4 |
B |
$1.81 |
$905,000 |
D/D |
500,000 |
580,944 |
2.74 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-10-04 |
4 |
B |
$1.28 |
$839,029 |
D/D |
653,449 |
790,583 |
2.45 |
- |
|
| Lampert Mark N |
10% Owner |
– – • |
2017-10-03 |
4 |
B |
$1.24 |
$1,169,047 |
D/D |
946,597 |
727,541 |
2.45 |
- |
|
| Perkins Adelene Q |
Chief Executive Officer |
• • – |
2017-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
85,800 |
535,020 |
|
- |
|
| Tasker Seth A |
General Counsel |
• – – |
2017-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
8,916 |
17,833 |
|
- |
|
| Bloch Lawrence E |
President |
• – – |
2017-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
39,039 |
80,944 |
|
- |
|
227 Records found
|
|
Page 2 of 10 |
|
|
